This subunit is only present in two heterodimeric integrins, α4β7 and αEβ7.1 Therapeutic targeting of α4β7:MAdCAM-1-mediated lymphocyte trafficking to the gut in inflammatory bowel disease [IBD] has been clinically validated. Here, MADCAM1 is linked to inflammatory bowel disease.